Proteomics Market Report 2025

The proteomics market size has grown rapidly in recent years. It will grow from $34.83 billion in 2024 to $39.71 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The growth in the historic period can be attributed to increase in government funds for research on proteomics, advancement in technologies, rise in healthcare expenditure, growth in the number of healthcare facilities and economic growth in emerging markets.

The proteomics market size is expected to see rapid growth in the next few years. It will grow to $66.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to increasing financing for proteomics ventures, rising requirement for customized medicine, increasing research and development activities and growth in investments in biotech companies attributing to COVID-19 outbreak. Major trends in the forecast period include focus on considering nanotechnology for identifying low-abundant samples, developing and advancing new technologies, launching new products, invest in technology such as artificial intelligence (ai) and real time improved imaging.

The advancement of the proteomics market is propelled by the increasing allocation of government funds towards proteomics research. Government funding serves as a crucial support for researchers engaged in drug discovery, disease diagnosis, and treatment. A case in point is Proteomics International Laboratories Limited, an Australia-based medical technology company, which, in May 2022, secured $400,000 in funding to enhance its manufacturing capabilities in Australia. This financial support aims to facilitate the production advancement of the PromarkerD test in Australia and South-East Asia, involving the expansion of Proteomics International's specialized ISO 13485 certification. Consequently, the rise in government funds has a positive impact on the proteomics market.

The expanding pharmaceutical industry is anticipated to drive the future growth of the proteomics market. The pharmaceutical sector, dedicated to the research, development, manufacturing, and distribution of drugs and medications, heavily relies on proteomics for drug development. Proteomics plays a vital role in identifying, characterizing, and monitoring proteins for drug targets and biomarker discovery. For example, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association, in June 2023, the total pharmaceutical production in Europe reached $400.2 billion (€340,000 million) in 2022, indicating an increase from $381.64 billion (€323,950 million) in 2021. Hence, the burgeoning pharmaceutical industry acts as a driving force for the growth of the proteomics market.

Companies are launching new products to boost their revenue and gain a competitive edge over their rivals. For example, in June 2022, Bruker Corporation, a US-based manufacturer of scientific instruments, introduced the latest advancement in its 4D Multiomics timsTOF platform with the new timsTOF HT system. This system features an innovative 4th-generation TIMS (trapped ion mobility separation) XR cell and a 14-bit digitizer, providing an expanded dynamic range, improved peptide coverage, and enhanced quantitation accuracy, particularly in unbiased 4D plasma and tissue proteomics, as well as epiproteomics.

Key players in the proteomics market are strategically focusing on the development of precise quantitative analysis kits to enhance their competitive position. These kits are instrumental in accurately measuring protein expression levels and identifying biomarkers across various biological samples. For instance, in January 2023, SCIEX, a US-based manufacturer of mass spectrometry instrumentation, launched the Fast Glycan Labeling and Analysis kit and an update for the Biologics Explorer software. This kit is specifically designed for precise quantitative glycan analysis, while the software update aims to enhance key workflows for the analysis of protein therapeutics. These solutions accelerate the examination and identification of glycans associated with proteins, providing researchers with advanced resources for comprehensive biopharmaceutical analysis. The software empowers researchers to make informed decisions regarding the most suitable analytical methods and tools for their specific applications, ultimately improving the efficiency and effectiveness of protein characterization studies.

In July 2024, Thermo Fisher Scientific, a US-based life science and clinical research company, acquired Olink Holding for approximately $3.1 billion. This acquisition aligns with Thermo Fisher's strategy to enhance its portfolio of innovative technologies. The company intends to leverage Olink's proprietary Proximity Extension Assay (PEA) technology, which facilitates high-throughput protein analysis for quantitative polymerase chain reaction and next-generation sequencing readout systems. PEA features a library of over 5,300 validated protein biomarker targets, significantly enhancing Thermo Fisher's capabilities in proteomics research. Olink Holding is a Sweden-based provider of next-generation proteomics solutions.

Major companies operating in the proteomics market include Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., Promega Corporation, Waters Corporation, Creative Proteomics, Sino Biological, EIAab, DIMA Biotechnology, TechnoConcept India Pvt. Ltd., Cellular & Molecular Biology, GE Healthcare, Perseus Proteomics Inc., JEOL, APTBIO, Leisure Science (Suzhou) Co. Ltd., Centre for Cellular & Molecular Biology, Vproteomics, Shimadzu Corporation, Abcam plc, IRB Barcelona, SGS UK, MRM Proteomics Inc., FingerPrints, Biognosys AG, Olink Proteomics, Horiba, MS Bioworks, LC Sciences, MtoZ Biolabs, Integrated Proteomics Applications, Quantumbio Inc., Luminex Corporation, Applied Biomics Inc., Isoplexis Corporation, Caprion Proteomics Inc.

North America was the largest region in the proteomics market in 2024. Western Europe was the second largest region in the global proteomics market share. The regions covered in the proteomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proteomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Proteomics involves the examination of the structure and functions of proteins, playing a crucial role in drug discovery, disease diagnosis, and treatment. It is employed to assess the production rate of proteins, the participation of proteins in metabolic pathways, and the modifications undergone by proteins.

The primary categories of proteomics include protein microarrays, spectroscopy, X-ray crystallography, chromatography, electrophoresis, surface plasmon resonance, and protein fractionation. The essential elements utilized in proteomics encompass reagents, instruments, and software, all contributing to proteomic analytical services and instrument services.

The proteomics market research report is one of a series of new reports that provides proteomics market statistics, including proteomics industry global market size, regional shares, competitors with a proteomics market share, detailed proteomics market segments, market trends, and opportunities, and any further data you may need to thrive in the proteomics industry. This proteomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteomics market consists of sales of proteins that are used for drug discovery, clinical diagnosis, molecular medicine and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.